

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|--|-----------|---|
| (51) International Patent Classification ⁶ : C07K 16/00 | A1 | (11) International Publication Number: WO 97/46588 (43) International Publication Date: 11 December 1997 (11.12.97) |
| (21) International Application Number: PCT/US97/07944 (22) International Filing Date: 14 May 1997 (14.05.97) (30) Priority Data: 60/018,958 4 June 1996 (04.06.96) US (71) Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 22nd floor, 300 Lakeside Drive, Oakland, CA 94612 (US). (72) Inventors: MOSTOV, Keith, E.RICHMAN-EISENSTAT, Janice (74) Agents: WEBER, Kenneth, A. et al.; Townsend and Townsend and Crew LLP, 8th floor, Two Embarcadero Center, San Francisco, CA 94111 (US). | | (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> |
| (54) Title: CELLULAR INTERNALIZATION OF PIGR STALK AND ASSOCIATED LIGANDS (57) Abstract Compositions and methods for specific binding to the stalk of a polymeric immunoglobulin receptor (pIgR) of a cell with the proviso that the ligand does not substantially bind to secretory component of pIgR under physiological conditions. The ligand may be targeted to, into, or across the cell and may comprise a biologically active composition. | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakhstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LJ | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

5 **CELLULAR INTERNALIZATION OF PIGR STALK AND
ASSOCIATED LIGANDS**

FIELD OF THE INVENTION

10 The present invention relates, in general, to compositions and
methods for the specific binding of a ligand to the stalk region of the polymeric
immunoglobulin receptor for internalization into, or transport across, a cell.

BACKGROUND OF THE INVENTION

15 One of the most challenging problems facing the pharmaceutical
and biopharmaceutical industries is delivering therapeutic agents past the
various semi-permeable membranes within the body. Particularly in the case of
macromolecules, the obstacle to cost effective or convenient treatment is often
due to the lack of an adequate drug delivery system. In turn, this issue
dictates whether production of a drug is economically feasible. Thus the
20 search for alternative delivery systems often rivals the search for new drugs
themselves.

 Gene transfer methods can be viewed as a paradigm of
macromolecular drug delivery. These methods can be divided into three
categories: physical (e.g., electroporation, direct gene transfer, and particle
25 bombardment), chemical (e.g., proteinoids, microemulsions, and liposomes),
and biological (e.g., virus-derived vectors, and receptor-mediated uptake).
Amongst biological transfer methods, receptor-mediated uptake is a particularly
promising approach. Targeting a ligand to an endocytosed receptor acts as a
means to ferry that ligand into the cell. However, one drawback of receptor-
30 mediated systems has been their general reliance on intravenous administration
which severely limits their use.

 Mucosal epithelial cells line a number of readily accessible tissues
such as those found in the upper respiratory and gastrointestinal tracts. The

accessibility of these cells make them an attractive target for drug delivery. See, e.g., Ferkol et al., *J. Clin. Invest.* 92:2394-2400 (1993); Ferkol et al., *J. Clin. Invest.* 95:493-502 (1995). Retrograde transport of an antibody from the luminal to the basolateral surface of epithelial cells has been reported, albeit at very low levels. Breitfeld *et al.*, *J. Cell Biology* 109:475-486 (1989). In that study, movement across the cell was followed by binding an antibody to the secretory component of polymeric immunoglobulin receptor (pIgR). Relative to the level of basolateral to apical transport, Breitfeld et al. reported that less than 5% of the transport was retrograde in nature. The nominal level of counter-transport minimizes the utility of secretory component as a means to deliver biologically active compositions into cells. Moreover, due to the abundance of cleaved pIgR in the lumen, binding of ligand to cleaved pIgR, rather than the intact pIgR of the cell surface, would diminish the utility of pIgR counter-transport as a mechanism of drug delivery.

Accordingly, what is needed in the art is a means to convey ligands into or across a cell surface with high efficiency. More particularly, what is needed in the art is a means to deliver macromolecules to, into, or across cells lining the gastrointestinal or respiratory tracts. The present invention provides these and other advantages.

SUMMARY OF THE INVENTION

In one aspect, the present invention is directed to a ligand that binds specifically to the stalk of a polymeric immunoglobulin receptor (pIgR) of a cell with the proviso that the ligand does not substantially bind to secretory component of pIgR under physiological conditions. Typically, the antibody specifically binds only to the stalk. In one embodiment, the ligand is an antibody, preferably a humanized antibody. In another embodiment the ligand is a recombinant single chain variable region fragment of an antibody. In yet another embodiment the ligand binds to an extracellular epitope within the first 33 amino acids that are cell membrane proximal to a cleavage site of the receptor.

The ligand may comprise a binding component for binding to the stalk, and a biologically active component such as a nucleic acid, protein,

radioisotope, lipid, and carbohydrate. Biologically active components comprise anti-inflammatories, anti-infectives, anti-sense oligonucleotides, antibiotics, and anti-infectives. In one embodiment, the biologically active component is a nucleic acid encoding a wildtype cystic fibrosis transmembrane conductance regulator. In a preferred embodiment the cell is an epithelial cell, most preferably a mammalian epithelial cell.

In another aspect, the present invention is directed to a method of introducing a ligand into a cell expressing a polymeric immunoglobulin receptor by attaching the ligand to the stalk of the polymeric immunoglobulin receptor of the cell with the proviso that the ligand does not substantially bind to the secretory component of plgR under physiological conditions. In one embodiment, the ligand is attached to the stalk at the apical surface of a cell; and in further embodiments, the ligand is transcytosed to the basolateral surface of the cell, and released from the stalk at the basolateral surface.

In a further aspect, the present invention relates to a method of attaching a ligand to a cell expressing a polymeric immunoglobulin receptor comprising the step of binding the ligand to a stalk of the receptor with the proviso that the ligand does not substantially bind to secretory component of plgR under physiological conditions. In one embodiment, the ligand is introduced into the cell after binding. Alternative embodiments of the present invention may be had by reference to the various aspects of the present invention.

Amongst the various in vivo and in vitro utilities, the present invention may be used to transport therapeutic or diagnostic compositions to, into, or across, mucosal epithelial cells. Thus, the invention provides a highly efficient and convenient means to transfer nucleic acids or proteins into epithelial cells.

DESCRIPTION OF THE PREFERRED EMBODIMENT

The present invention is directed to a ligand that binds specifically to the stalk of a polymeric immunoglobulin receptor (plgR) of a cell with the proviso that the ligand does not substantially bind to secretory component of plgR under physiological conditions. The invention provides, *inter alia*, methods

of attaching and introducing a ligand into a cell expressing plgR.

After transport to the apical surface of epithelial cells, the majority of plgR is cleaved and secretory component is released. We have discovered that, surprisingly and unexpectedly, cleavage of intact plgR in the lumen leaves
5 a residual extracellular region of plgR (i.e., the "stalk") intact; and further, the stalk remains accessible to binding despite the abundance of proteases typically present in luminal milieu. The ability to bind, endocytose, and transcytose a ligand bound to the plgR stalk provides, in part, the invention as disclosed and claimed herein.

10 The present invention has utility as a means of transporting therapeutic or diagnostic compositions to, into (endocytosis) or across (transcytosis) a cell expressing plgR. Thus the invention can be used to transport biologically active compositions such as proteins, nucleic acids, or detectable labels specifically to cells expressing plgR. The invention also
15 provides a means of labeling and distinguishing epithelial cells from amongst a mixed cell population in pathological studies. Further, since plgR expression is reduced in carcinomas relative to normal epithelium, the labeling of plgR has utility as a diagnostic adjunct in endoscopic or radiologic procedures. Additionally, binding of therapeutic ligands to plgR has utility in extending their
20 duration in the lumen of various passageways and increasing their effectiveness.

Definitions

Unless defined otherwise herein, all technical and scientific terms
25 used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Singleton *et al.* (1994) *Dictionary of Microbiology and Molecular Biology*, second edition, John Wiley and Sons (New York), and Hale and Marham (1991) *The Harper Collins Dictionary of Biology*, Harper Perennial, NY provide one of skill with a general
30 dictionary of many of the terms used in this invention. Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their

commonly accepted single-letter codes. For purposes of the present invention, the following terms are defined below.

By "ligand" or "ligand binding moiety", is meant all molecules capable of specifically binding to the polymeric immunoglobulin receptor (pIgR).
5 Ligands include, but are not limited to, antibodies, proteins, peptides, nucleic acids, lipids, and carbohydrates.

By "biologically active component" is meant a compound which, in vivo, directly causes or inhibits an increase or decrease in cellular transcription, translation, receptor binding, active or passive transport, cell signaling, signal
10 transduction, cell division, cell differentiation, cell death, cell adhesion, cell movement, cell morphology, metabolism, enzyme activity, apoptosis, protein degradation, protein movement (e.g., secretion), protein stability, or phosphorylation. Biologically active components also comprise diagnostic compositions which allow the foregoing events to be assessed.

By "bind(s) specifically" or "specifically bind(s)" or "attached" or "attaching" is meant the preferential association of a ligand, in whole or part, with a cell or tissue bearing a particular target molecule or marker and not to cells or tissues lacking that target molecule. It is, of course, recognized that a certain degree of non-specific interaction may occur between a molecule and a
20 non-target cell or tissue. Nevertheless, specific binding, may be distinguished as mediated through specific recognition of the target molecule. Typically specific binding results in a much stronger association between the delivered molecule and cells bearing the target molecule than between the bound molecule and cells lacking the target molecule. Specific binding typically
25 results in greater than 2 fold, preferably greater than 5 fold, more preferably greater than 10 fold and most preferably greater than 100 fold increase in amount of bound ligand (per unit time) to a cell or tissue bearing the target molecule as compared to a cell or tissue lacking the target molecule or marker.

By "stalk" is meant the extracellular component of the polymeric
30 immunoglobulin receptor (pIgR) that corresponds to that region of pIgR that is bound to the cell following cleavage of that segment of pIgR which constitutes the secretory component. The stalk is present regardless of whether the segment of pIgR which corresponds to secretory component is cleaved or

uncleaved from plgR.

By "plgR" or "polymeric immunoglobulin receptor" is meant the receptor which is expressed in mucosal epithelial cells, including airway epithelial cells, submucosal gland cells, intestinal cells, nasal epithelium, breast,
5 oral mucosa, urinary and reproductive tract epithelium, and conjunctival tissue, and is implicated in basolateral to apical transcytosis of dimeric immunoglobulin A (dIgA) and/or pentameric IgM.

By "not substantially bind" is meant that no more than 15% of a ligand which specifically binds to a target molecule is bound to a particular non-
10 target molecule. More preferably, no more than 10% is bound to the non-target molecule, even more preferably less than 5%, and most preferably less than 1%.

By "secretory component" is meant that extracellular portion of plgR which is generally cleaved following basolateral to apical transcytosis.
15 Typically, the secretory component comprises the dimeric IgA (dIgA) binding portion of plgR. Secretory component is typically released into the lumen with or without dIgA bound to the secretory component.

By "physiological conditions" is meant an extracellular milieu having conditions (e.g., temperature, pH, and osmolarity) which allows for the
20 sustenance or growth of a cell of interest.

By "antibody" is meant an immunoglobulin molecule obtained by in vitro or in vivo generation of the humoral response, and includes both polyclonal and monoclonal antibodies. The term also includes genetically engineered forms such as chimeric antibodies (e.g., humanized murine
25 antibodies), heteroconjugate antibodies (e.g., bispecific antibodies), and recombinant single chain Fv fragments (scFv). The term "antibody" also includes antigen binding forms of antibodies (e.g., Fab, F(ab)₂).

By "humanized antibody" is meant an antibody which comprises a non-human amino acid sequence but whose constant region has been altered to
30 reduce immunogenicity in humans.

By "wildtype cystic fibrosis transmembrane conductance regulator" is meant a functional form of the cystic fibrosis transmembrane conductance regulator (CFTR). Riordan et al., Science, 245:1066-1073 (1989).

By "apical surface " is meant that surface of a cell to which intact plgR is transcytosed to after endocytosis from the basolateral surface. Generally, the apical surface of the cell adjoins a lumen and therein intact plgR is cleaved to release the secretory component.

5 By "basolateral surface" is meant that surface of a cell from which intact plgR is delivered to after synthesis in the endoplasmic reticulum and passage through the Golgi complex.

By "surface of the stalk" is meant the extracellular region of the stalk.

10 By "released" is meant the interference in the specific association of a ligand, in whole or part, with its target molecule.

By "transcytosed" or "transcytosis" is meant conveyance from one plasma membrane of the cell to another via an intracellular route. Typically, transcytosis occurs from the basolateral to apical or apical to
15 basolateral plasma membrane of the cell.

By "cell membrane proximal" is meant next to or nearer the cell membrane.

By "extracellular" is meant the region extending outward from the lipid bilayer encompassing a cell.

20

Identification of plgR

The nucleic acid and amino acid sequence of the polymeric immunoglobulin receptor has been identified in a variety of taxonomically diverse species. See, Piskurich *et al.*, *Journal of Immunology* 154:1735-1747
25 (1995). Identification of plgR from other species can be accomplished by any number of methods well known to those of skill in the art. For example, using published plgR sequences a nucleic acid probe to plgR can be constructed. The probe typically should be derived from a conserved region of plgR. Hybridization of the probe to a genomic or cDNA library can be used to identify
30 plgR in an unknown species. It will be understood by the skilled artisan that the nucleic acid sequence of the plgR probe should generally be that of the species most closely related to the probed species. An extensive guide to the hybridization of nucleic acids is found in Tijssen (1993) *Laboratory Techniques*

in Biochemistry and Molecular Biology--Hybridization with Nucleic Acid Probes
Part I, Chapter 2 "Overview of principles of hybridization and the strategy of
nucleic acid probe assays", Elsevier, New York.

In an alternative approach, plgR or peptide fragments thereof (e.g.,
5 secretory component) can be used to create antibodies to screen expression
libraries. See, e.g., Ferkol *et al.*, *J. Clin. Invest.* 95:493-502 (1995). These
and other methods well known to the skilled artisan may be found, for
example, in Berger and Kimmel, *Guide to Molecular Cloning Techniques*,
Methods in Enzymology volume 152 Academic Press, Inc., San Diego, CA
10 (Berger); Sambrook *et al.* (1989) *Molecular Cloning - A Laboratory Manual* (2nd
ed.) Vol. 1-3; and *Current Protocols in Molecular Biology*, F.M. Ausubel *et al.*,
eds., Current Protocols, a joint venture between Greene Publishing Associates,
Inc. and John Wiley & Sons, Inc., (1994 Supplement) (Ausubel). Confirmation
of the identity of a nucleic acid or protein as encoding plgR may be had by
15 such approaches as constructing antibodies to the putative plgR protein and
confirming the ability of these antibodies to bind to a protein having the
characteristics of plgR (e.g., being present on the surface of epithelial cells,
binding of dimeric IgA or pentameric IgM, etc.).

20 Identification of the Stalk

The stalk can be identified by a variety of techniques well known
to those of skill. A putative heptapeptide consensus sequence which identifies
the cleavage site of plgR and thereby defines the amino terminus of the stalk
has been identified. The sequence Phe-Ala-Xaa-Glu (SEQ ID NO:1), where Xaa
25 is a polar or charged amino acid, was identified as immediately preceding this
putative cleavage site. Piskurich *et al.*, *Journal of Immunology* 154:1735-1747
(1995). Cleavage at the consensus site liberates the secretory component and
defines its carboxy terminus. The carboxy terminus of secretory component
may be altered by secondary cleavage events (e.g., exopeptidase or
30 endopeptidase activity) to yield secondary carboxy termini. *Id.* However, the
amide linkage which initially defines the amino terminus of the stalk and the
carboxy terminus of secretory component may be identified by sequence
alignment and identification of the cleavage consensus sequence.

Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison may be conducted by the local homology algorithm of Smith and Waterman (1981) *Adv. Appl. Math.* 2: 482; by the homology alignment algorithm of Needleman and Wunsch (1970) *J. Mol. Biol.* 48: 443; by the search for similarity method of Pearson and Lipman (1988) *Proc. Natl. Acad. Sci. USA* 85: 2444; by computerized implementations of these algorithms (including, but not limited to CLUSTAL in the PC/Gene program by Intelligenetics, Mountain View, California, GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, Wisconsin, USA); the CLUSTAL program is well described by Higgins and Sharp (1988) *Gene*, 73: 237-244 and Higgins and Sharp (1989) *CABIOS* 5: 151-153; Corpet, *et al.* (1988) *Nucleic Acids Research* 16, 10881-90; Huang, *et al.* (1992) *Computer Applications in the Biosciences* 8, 155-65, and Pearson, *et al.* (1994) *Methods in Molecular Biology* 24, 307-31. Alignment is also often performed by inspection and manual alignment.

In another approach, secretory component can be isolated from fluids in the apical lumen (e.g., milk or bile) and sequenced by amino acid sequencing methods well known to those of skill such as Edman degradation, or mass spectrometry. Eifert *et al.*, *Hoppe-Seyler's Z. Physiol. Chem.* 365:1489-1495 (1984). Amongst the various secondary carboxyl ends defined by secondary cleavage events, the carboxy terminal amino acid adjacent to the cleavage site can be identified.

Peptides which correspond to the plgR stalk of selected species include:

Mouse: Glu-Arg-Glu-Ile-Gln-Asn-Val-Arg-Asp-Gln-Ala-Gln-Glu-Asn-Arg-Ala-Ser-Gly-Asp-Ala-Gly-Ser-Ala-Asp-Gly-Gln-Ser-Arg-Ser-Ser-Ser-Lys (SEQ ID NO:2)

Rat: Glu-Arg-Glu-Ile-Gln-Asn-Ala-Gly-Asp-Gln-Ala-Gln-Glu-Asn-Arg-Ala-Ser-Gly-Asn-Ala-Gly-Ser-Ala-Gly-Gly-Gln-Ser-Gly-Ser-Ser-Lys (SEQ ID NO:3)

Human: Glu-Lys-Ala-Val-Ala-Asp-Thr-Arg-Asp-Gln-Ala-Asp-Gly-Ser-Arg-Ala-Ser-Val-Asp-Ser-Gly-Ser-Ser-Glu-Glu-Gln-Gly-Gly-Ser-Ser-Arg (SEQ ID NO:4)

5 Bovine: Glu-Ser-Val-Lys-Asp-Ala-Ala-Gly-Gly-Pro-Gly-Ala-Pro-Ala-Asp-Pro-Gly-Arg-Pro-Thr-Gly-Tyr-Ser-Gly-Ser-Ser-Lys (SEQ ID NO:5)

Rabbit: Leu-Ala-Glu-Val-Ala-Val-Gln-Ser-Ala-Glu-Asp-Pro-Ala-Ser-Gly-Asp-Pro-Ala-Ser-Gly-Ser-Arg-Ala-Ser-Val-Asp-Ser-Gly-Ser-Ser-Glu-Glu-Gln-Gly-Gly-Ser-Ser-Arg-Ser-Lys (SEQ ID NO:6)

10

Cells Expressing plgR

While the present invention broadly pertains to eukaryotic cells. The plgR expressing cell of the present invention is preferably a mammalian cell and more preferably a mammalian epithelial cell that normally secretes IgA.

15 Mammalian cells can be transfected with a nucleic acid encoding plgR isolated, synthesized or otherwise derived from one or more desired species. Methods of transfecting and expressing genes in mammalian cells are known in the art. Transducing cells with viral vectors can involve, for example, incubating viruses

20 with cells within the viral host range under conditions and concentrations necessary to cause infection. See, e.g., *Methods in Enzymology*, vol. 185, Academic Press, Inc., San Diego, CA (D.V. Goeddel, ed.) (1990) or M. Krieger, *Gene Transfer and Expression -- A Laboratory Manual*, Stockton Press, New York, NY, (1990) and the references cited therein.

25 The culture of cells which can be used in the present invention include cell lines and cultured cells from tissue or blood samples is well known in the art. Freshney (*Culture of Animal Cells, a Manual of Basic Technique, third edition* Wiley-Liss, New York (1994)) and the references cited therein provides a general guide to the culture of cells. The nucleic acid sequences

30 encoding plgR from the desired species may be expressed in a variety of eukaryotic host cells, including yeast, and various high r eukaryotic cells such as th COS, CHO and HeLa cells lines and my loma c ll lines as w ll as MDCK and human colon carcinoma derived cells such as Caco2. The recombinant

protein gene will be operably linked to appropriate expression control sequences for each host. For eukaryotic cells, the control sequences will include a promoter and preferably an enhancer derived, for example, from immunoglobulin genes, SV40, cytomegalovirus, etc., and a polyadenylation sequence, and may include splice donor and acceptor sequences.

Binding Ligands to the Stalk

The specific stalk binding ligand is not critical to this invention and various ligands may be used. A host of methods for construction and selection of ligands such as nucleic acids, proteins or peptides (collectively, "peptides), or antibodies, or small organics or inorganics (e.g., U.S. Pat. No. 5,143,854; WO 90/15070; WO 92/10092; WO 96/11878) having the desired specific binding characteristics are well known in the art. Preferably, ligands of the present invention will, under physiological conditions, bind to the stalk without substantially binding to the secretory component of plgR. More preferably, the ligands of the present invention specifically bind only to the stalk under physiological conditions. Typical physiological conditions vary from tissue to tissue. However, exemplary physiological conditions are encountered in the gastrointestinal or respiratory tract of mammals, including but not limited to humans. A ligand may be chosen to bind to an extracellular ligand binding site ("epitope") contained within the first 6, 9, 12, 15, 18, 21, 24, 27, 30, or 33 membrane proximal amino acids of the stalk.

Antibodies, including polyclonal, monoclonal, or recombinant single chain Fv antibodies, can be constructed for use as ligands in the present invention. Methods of producing polyclonal and monoclonal antibodies are known to those of skill in the art. See, e.g., Coligan (1991) *Current Protocols in Immunology* Wiley/Greene, NY; and Harlow and Lane (1989) *Antibodies: A Laboratory Manual* Cold Spring Harbor Press, NY; Stites *et al.* (eds.) *Basic and Clinical Immunology* (4th ed.) Lange Medical Publications, Los Altos, CA, and references cited therein; Goding (1986) *Monoclonal Antibodies: Principles and Practice* (2d ed.) Academic Press, New York, NY; and Kohler and Milstein (1975) *Nature* 256: 495-497; See, Huse *et al.* (1989) *Science* 246: 1275-1281; and Ward, *et al.* (1989) *Nature* 341: 544-546. Birch and Lennox,

Monoclonal Antibodies: Principles and Applications, Wiley-Liss, New York, New York (1995).

Other suitable techniques for antibody or peptide ligand preparation include selection of libraries of recombinant antibodies/peptides in phage or similar vectors. High affinity antibodies and peptides to the stalk can be rapidly isolated by using phage display methods to express recombinant single chain Fv (scFv) fragments or peptide ligands on the phage surface. Briefly, genes encoding the surface protein of a phage are altered so as to allow the insertion of an antibody or peptide gene which is expressed as a fusion protein on the surface of the phage that carries the gene. The phage expressing the desired antibody or peptide ligand can be selectively enriched and isolated by virtue of its affinity/avidity for the stalk. The DNA encoding the ligand is packaged in the same phage and which allows the gene encoding the ligand to be isolated. A variety of such methods are amply discussed in the literature and well known to the skilled artisan. See, e.g., Winter *et al.*, *Annu. Rev. Immunol.* 12:433-455 (1994); Marks *et al.*, *J. Mol. Biol.* 222:581-597 (1991); Vaughan *et al.*, *Nature Biotechnology* 14:309-314 (1996), US Pat Nos. 4,642,334; 4,816,397; 4,816,567; 4,704,692; WO 86/01533; WO 88/09344; WO 89/00999; WO 90/02809; WO 90/04036; EP 0 324 162; EP 0 239 400.

In chemical peptide synthesis, a procedure termed "Divide, Couple and Recombine" (DCR) has been used to produce combinatorial peptide libraries. See, Furka *et al.*, *Int. J. Pept. Protein Res.* 37:487-493 (1991) and Houghten *et al.*, *Nature* 354:84-86 (1991). As an alternative to DCR, peptide mixtures have also been made by direct coupling of monomer mixtures. See, Rutter *et al.*, U.S. Patent No. 5,010,175. The use of such methods to produce mixtures of other linear polymers, such as "peptoids", has been suggested. See, Simon, *et al.*, *Proc. Natl. Acad. Sci. USA* 89:9367-9371 (1992). In oligonucleotide synthesis, "degenerate" or "wobble" mixtures of oligonucleotide products can be made by, for example, delivery of equimolar mixtures of monomers to an oligonucleotide polymer at specific steps during synthesis. See, Atkinson and Smith, in "Oligonucleotide Synthesis. A Practical Approach", 1984, IRL Press, Oxford, edited by M. Gait, pp 35-81. These

methods of synthesizing peptides or oligonucleotides provide large numbers of compounds for testing which, if active, can be readily identified.

Preferably, ligands will be constructed to minimize immunogenicity in the host as, for example, by maximizing the number of autologous (self) sequences present in the ligand. Accordingly, chimeric antibodies having non-xenogenic variable regions are preferred. Particularly preferred are the use of antibodies in which xenogenic portions are excluded, or are essentially limited to the complementarity determining regions as in humanized antibodies.

10 Ligand Binding and Testing

Binding (i.e., attachment) of the ligand to the stalk of plgR may occur prior or subsequent to cleavage of secretory component; and the ligand may be attached at the basolateral or apical surface. Thus, the ligand can be endocytosed basolaterally or apically, or be subject to apical to basolateral, or basolateral to apical transcytosis. The fate of the ligand, or any element thereof, will vary according to its physico-chemical characteristics.

Accordingly, the properties of the ligand may be selected or designed to perform the desired function at the cell surface, within the endosome, or following transcytosis. For example, varying the sensitivity of a ligand to proteolytic or reducing environments can be used to determine the distribution of ligand bound, internalized, or transported across the cell. Where desirable, a ligand may be designed to remain specifically bound to the cell following attachment or transcytosis or, alternatively, to be released into the extracellular milieu. Thus, the properties of any of the various elements of the ligand, including the binding component, biologically active component or linker, may be designed or selected to allow for different degrees of affinity, stability, or activity at different intracellular compartments or surfaces of the cell, as desired.

A. Ex Vivo Testing of Ligand Binding

In vitro binding of the ligand to the stalk may be conveniently assessed by measuring endocytosis or transcytosis of bound ligand in mammalian epithelial cells. "Endocytosis" refers generally to the phenomenon of a cell ingesting material, *e.g.*, by phagocytosis or pinocytosis. Receptor-mediated endocytosis provides an efficient means of causing a cell to ingest material which binds to a cell surface receptor. See, Wu and Wu (1987) *J. Biol. Chem.* 262:4429-4432; Wagner *et al.* (1990) *Proc. Natl. Acad. Sci. USA* 87:3410-3414, and EP-A1 0388 758. Any number of well known methods for assaying endocytosis may be used to assess binding. For example, binding, transcytosis, and internalization assays are described at length in Breittfeld *et al. J. Cell Biol.* 109:475-486 (1989).

Apical endocytosis is conveniently measured by binding a ligand such as a Fab fragment to the stalk at the apical surface of Madin-Darby canine kidney (MDCK) cells at 4°C, warming to 37°C for brief periods (0-10 min), and cooling the cells back down to 4°C. Methods of plgR expression in MDCK cells is well known in the art. Breittfeld *et al., Methods in Cell Biology* 32:329-337 (1989). Fab remaining on the surface are removed by stripping at pH 2.3. Intracellular Fab are those that remain cell-associated after the stripping, while surface-bound Fab are those removed by the acid wash. Controls for non-specific sticking include using pre-immune Fab and/or MDCK cells that are not transfected with plgR.

Transcytosis can be readily assessed by allowing MDCK cells to bind the Fab at the apical surface at 4°C, warming up to 37°C for 0-240 min, and then measuring the amount of Fab delivered into the basolateral medium. This basolaterally-delivered Fab is compared to the sum of Fab that remains associated with the cells (intracellular or acid-stripped) and the Fab released back into the apical medium. Alternatively, transcytosis can be assessed by continuously exposing cells to the Fab in the apical medium and measuring accumulation of Fab in the basolateral medium. This method avoids cooling the cells, but does not provide the kinetics of transporting a single cohort of ligand. In both methods degradation of the Fab can be assessed by running aliquots of the transcytosed Fab on SDS-PAGE and probing a Western with anti-chicken

antibodies. Non-specific transport (e.g. due to fluid phase endocytosis and transcytosis, or paracellular leakage between cells) can be controlled for by using MDCK cells that are not transfected with the plgR and/or pre-immune Fab.

5

B. In Vivo Testing of Ligand Binding

Transcytosis in vivo may conveniently be assessed using pathogen-free experimental animals such as Sprague-Dawley rats. Labelled ligand (e.g., radioiodinated antibody) can be administered into the nares. As will be understood by those of skill in the art, a "label" is a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, electromagnetic, radiochemical, or chemical means such as fluorescence, chemifluorescence, or chemiluminescence. Apical to basolateral transcytosis can be readily determined by measuring delivery of the ligand into the circulation as determined by the presence of label. The integrity of the ligand recovered from the circulation can be assessed by analyzing the ligand on SDS polyacrylamide gel electrophoresis.

10
15

Biologically Active Component

The biologically active component of the ligand may be covalently or non-covalently bound to the ligand. For example, chelators may be used to bind various isotopes, or nucleic acids may be bound to the ligand via hydrogen bonds. Biologically active components may also be encompassed within emulsions, proteinoids, or liposomes. As those skilled in the art will understand, such structures may be linked covalently to the ligand via derivatized polar head groups or via membrane integral proteins. Binding components of the ligand may also comprise the biologically active component.

20
25

Biologically active components comprise any number of compounds known to those of skill as anti-inflammatories, cytokines, anti-infectives, enzyme activators or inhibitors, allosteric modifiers, or antibiotics. Thus, biologically active component includes such compounds as nucleic acids, proteins, peptides, amino acids or derivatives, glycoproteins, radioisotopes, lipids, carbohydrates, or recombinant viruses. The term "nucleic acid" refers

30

to a deoxyribonucleotide or ribonucleotide polymer in either single- or double-stranded form, and unless otherwise limited, encompasses known analogues of natural nucleotides. Nucleic acids include anti-sense nucleic acids, derivatized oligonucleotides for covalent cross-linking with single or duplex DNA, triplex
5 forming oligonucleotides, or nucleic acids encoding proteins or peptides. Nucleic acids also includes compositions for gene therapy such as those encoding for the wildtype cystic fibrosis transmembrane conductance regulator.

Attaching Biologically Active Compositions to the Ligand

10 The procedure for attaching a biologically active component to a ligand will vary according to the chemical structure of the component. Generally, the ligands will contain a variety of functional groups which are available for reaction with a suitable functional group on a biologically active molecule to bind the agent thereto. Alternatively, the ligand and/or biologically
15 active component may be derivatized to expose or attach additional reactive functional groups. The derivatization may involve attachment of any of a number of linker molecules such as those available from Pierce Chemical Company, Rockford Illinois. A "linker" as used herein refers to a molecule used to join, covalently or non-covalently, the ligand and biologically active
20 component. Suitable linkers are well known to those of skill in the art and include, but are not limited to, straight or branched-chain carbon linkers, heterocyclic carbon linkers, or peptide linkers. *See, e.g.,* Birch and Lennox, *Monoclonal Antibodies: Principles and Applications*, Chapter 4, Wiley-Liss, New York, New York (1995); US Pat Nos. 5,218,112, 5,090,914; Hermanson,
25 *Bioconjugate Techniques*, Academic Press, San Diego, CA (1996).

Where both molecules are polypeptides, the linkers may be joined to the constituent amino acids through their side groups (e.g., through a disulfide linkage to cysteine). A bifunctional linker having one functional group reactive with a group on a particular biologically active component, and another
30 group reactive with a ligand, may be used to form the desired conjugate. Alternatively, derivatization may involve chemical treatment of the component; e.g., glycol cleavage of the sugar moiety of the glycoprotein antibody with periodate to generate free aldehyde groups. The free aldehyde groups on the

antibody may be reacted with free amine or hydrazine groups on an agent to bind the agent thereto. (See U.S. Patent No. 4,671,958). Procedures for generation of free sulfhydryl groups on antibodies or antibody fragments are also known (See U.S. Pat. No. 4,659,839). Many procedure and linker
5 molecules for attachment of various compounds including radionuclide metal chelates, toxins and drugs to proteins such as antibodies are known. See, for example, European Patent Application No. 188,256; U.S. Patent Nos., 4,671,958, 4,659,839, 4,414,148, 4,699,784; 4,680,338; 4,569,789; and 4,589,071; and Borlinghaus *et al.* *Cancer Res.* 47: 4071-4075 (1987)).

10 It is sometimes desirable to release the conjugated molecule when it has reached a target site. Therefore, conjugates comprising linkages which are cleavable in the vicinity of the target site may be used. Cleaving of the linkage to release the biologically active component from the antibody may be prompted by enzymatic activity or conditions to which the conjugate is
15 subjected either inside the target cell or in the vicinity of the target site. When the target site is a tumor, a linker which is cleavable under conditions present at the tumor site (e.g. when exposed to tumor-associated enzymes or acidic pH) may be used. Use of the cis-aconitic acid spacer is useful for releasing biologically active components in endosomes. Similarly, disulfide linkages are
20 cleavable in the reductive environment of the endosomes.

A number of different cleavable linkers are known to those of skill in the art. See U.S. Pat. Nos. 4,618,492; 4,542,225, and 4,625,014. The mechanisms for release of an agent from these linker groups include, for example, irradiation of a photolabile bond and acid-catalyzed hydrolysis. U.S.
25 Patent No. 5,141,648 discloses immunoconjugates comprising linkers of specified chemical structure, wherein the linkage is cleaved in vivo thereby releasing the attached compound (radiotherapeutic agent, drug, toxin, etc.). The linker is susceptible to cleavage at a mildly acidic pH, and is believed to be cleaved during transport into the cytoplasm of a target cell, thereby releasing
30 the biologically active compound inside a target cell. U.S. Pat. No. 4,671,958 includes a description of immunoconjugates comprising linkers which are cleaved at the target site in vivo by the proteolytic enzymes of the patient's complement system. In view of the large number of methods that have been

reported for attaching a variety of radiodiagnostic compounds, radiotherapeutic compounds, drugs, toxins, and other components to ligands one skilled in the art will be able to determine a suitable method for attaching a given component to a ligand of the present invention.

5

Egress of the Ligand from the Endosome

A number of methods well known to the skilled artisan may be used to transport ligand, or any portion thereof, out of the endosome.

10 A poly-L-lysine/nucleic acid complex bound to a ligand which binds specifically to the stalk can be used for efficient transfection. Ferkol *et al.*, *J. Clin. Invest.*, 92:2394-2400 (1993); and Ferkol *et al.*, *J. Clin. Invest.*, 95:493-502 (1995).

15 In another approach, poly-L-lysine can be linked, such as by genetic fusion or chemical linkers, to a ligand that binds specifically to the stalk of plgR. In turn, this complex can be linked to defective adenovirus. Curiel and co-workers have demonstrated that naked plasmid DNA bound electrostatically to poly-L-lysine or poly-L-lysine-transferrin which has been linked to defective adenovirus mutants can be delivered to cells with transfection efficiencies approaching 90%. The adenovirus-poly-L-lysine-DNA
20 conjugate binds to the normal adenovirus receptor and is subsequently internalized by receptor-mediated endocytosis. This approach has been used to obtain as much as a 1000-fold increase in expression of gene therapy vectors. Herpes viruses have similar properties. Curiel *et al.* (1991) *Proc Natl Acad Sci USA* 88:8850-8854; Cotten *et al.* (1992) *Proc Natl Acad Sci USA*
25 89:6094-6098; Curiel *et al.* (1992) *Hum Gene Ther* 3:147-154; Wagner *et al.* (1992) *Proc Natl Acad Sci USA* 89:6099-6103; Michael *et al.* (1993) *J Biol Chem* 268:6866-6869; Curiel *et al.* (1992) *Am J Respir Cell Mol Biol* 6:247-252, and Harris *et al.* (1993) *Am J Respir Cell Mol Biol* 9:441-447); Gao *et al.* (1993) *Hum. Gene Ther.* 4:17-24; Curiel *et al.* U.S. Pat. App. SN
30 07/768,039.

In yet another approach using influenza virus, a hydrophobic peptid in the hemagglutinin can act as a fusion peptide at low pH to effect fusion of the virus with the membrane of the endosome and delivering the virus

into the cytoplasm. This peptide has been used in transferrin/peptide/poly-L-lysine/DNA complexes for gene transfer using the transferrin receptor and substantially improved the efficiency of expression. Wagner *et al.*, *Proc. Natl. Acad. Sci USA* 89:7934-7938 (1992). This peptide can be engineered into a
5 ligand for transport of the ligand, or a portion thereof, out of the endosome.

A further approach may employ ricin A. Ricin A chain is capable of penetrating out of endosome and into the cytosol. Beaumell *et al.*, *J. Biol. Chem.* 268:23661-23669 (1993). A ligand of the present invention may be linked to ricin A, such as by genetic fusion or chemical linkers.

10 Although the present invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims.

15 Example 1

Example 1 describes a method of producing and assaying for chicken antibodies and Fab fragments which specifically bind to the rabbit plgR stalk region.

The membrane-spanning segment of the rabbit plgR begins at the
20 Valine residue at position 630. The sequence of the twenty four extracellular residues of the rabbit plgR that precede the membrane-spanning segment is: 607-AspProAlaSerGlySerArgAlaSerValAspAlaSerSerAlaSerGlyGlnSerGlySerAlaLys-629 (SEQ ID NO:7).

Two peptides were synthesized (Immuno-Dynamics, Inc., La Jolla,
25 CA) representing the extracellular, membrane proximal 16 and 23 amino acids of plgR. A C-terminal cysteine was added for conjugation purposes. Peptide sequences (in single letter code) were: DPA SGS RAS VDA SSA SGQ SGS AKC (SEQ ID NO:8) for the primary peptide; and the subsequence peptide: ASV DAS SAS GQS GSA KC (SEQ ID NO:9). Half of each amount of peptide
30 was conjugated to keyhole limpet hemocyanin (KLH) (by Immuno-Dynamics, Inc).

The KLH-conjugated peptides were sent to Lampire Biological Laboratories (Pipersville, PA) for production of chicken antibodies in two

chickens per peptide. Lampire's standard protocol for chicken immunization was followed by collection of pre-immune eggs and a pre-immune test bleed; intramuscular injection of 2 mg of peptide with Freund's complete suspension at project initiation; intramuscular injection of 0.5 mg of peptide with Freund's incomplete suspension week 1; intramuscular injection of 0.25 mg of peptide with Freund's incomplete suspension week 2; rest week 3; intramuscular injection of 0.25 mg of peptide with Freund's incomplete suspension week 4; rest week 5, and test bleed week 6. Daily egg collection began around week 6 and monthly test bleeds were collected. Eggs were delivered monthly.

Upon arrival, egg yolks were carefully separated from egg whites, and stored at 4°C in 50-80 mls of basic buffer (0.01M sodium phosphate pH 7.5, 0.1M NaCl, 0.01% azide) per egg yolk until processed for extracting chicken antibody ("IgY"). IgY was extracted from batches of stored egg yolks by a series of PEG precipitations followed by a series of ammonium sulfate precipitations, according to the method of Polson et al. *Immunol Commun.* 9:475 (1980)). Briefly, solid PEG (polyethylene glycol, MW 8000) was added to yolks in basic buffer to 3.5% by weight of PEG to volume of diluted yolk, and stirred at room temperature until dissolved. The solution was centrifuged at 14,000g for 10 min at 20°C and decanted through a funnel containing a loose layer of absorbent cotton gauze. More PEG was added to the clear filtrate for a final PEG concentration of 12% to precipitate the IgY. After sedimenting the precipitate by centrifuging at 14,000g for 10min at 20°C, the precipitate was dissolved in 60 ml of basic buffer per yolk and an equal volume of 24% PEG in basic buffer was added to reform the precipitate. The precipitate was centrifuged twice more at 14,000g for 10 min at 20°C to remove all residual PEG solution. Pellets were dissolved in 30 mls of basic buffer per egg yolk, and the protein was precipitated in 50% saturated (NH₄)₂SO₄ by slowly adding an equal volume of saturated (NH₄)₂SO₄. and by stirring overnight at 4°C. The precipitate was centrifuged at 14,000g for 10 min at 4°C and the pellet was washed in an equal volume of cold 50% (NH₄)₂SO₄. The precipitate was centrifuged again at 14,000g for 10 min at 4°C, dissolved in PBS without calcium or magnesium, pH 7.5, and dialyzed extensively in PBS to remove all (NH₄)₂SO₄. Purity of the IgY preparation was confirmed by

SDS-PAGE (approx. 90-95%), and quantitation of IgY was estimated by measuring the absorbance at 280 nm and using an extinction coefficient of 1.3.

Affinity purification of IgY from chickens injected with the primary peptide of SEQ ID NO:8 was accomplished by first covalently linking the peptide to SULFOLINK coupling gel (Pierce Chemical Company), which allows binding specifically to sulfhydryl groups such as that on the C-terminal cysteine of the peptide. A 3 ml column was made with 3 mg of peptide according to the product instructions. Briefly, a 3 ml column was equilibrated with 6 column volumes of 50 mM Tris, 5 mM EDTA, pH 8.5, and then 3 mg of the primary peptide SEQ ID NO:8 in 3 ml 50 mM Tris, 5 mM EDTA pH 8.5 were added to the column for mixing at room temperature for 15 min. The column gel and peptide were incubated for another 30 min without mixing. The peptide buffer was drained off the gel and saved for later testing to confirm coupling efficiency using Ellman's reagent (DTNB (5,5'-dithiobis(2-nitrobenzoic acid), Pierce Chemical Company) which detects sulfhydryl groups. The primary peptide SEQ ID NO:8 does not contain any aromatic amino acid groups and could not be detected spectrophotometrically or by standard protein assay techniques, such as by Bradford analysis. Using Ellman's reagent according to the product instructions for comparison of an aliquot of peptide solution before and after binding to the gel, confirmed 100% binding efficiency. The gel column was washed with 3 column volumes of 50 mM Tris, 5 mM EDTA pH 8.5 before blocking nonspecific binding sites with 3 ml of cysteine solution in 50 mM Tris, 5 mM EDTA pH 8.5 for 15 min mixing at room temperature followed by 30 minutes without mixing. The column was drained, and washed with 16 column volumes of 1M NaCl and then with 16 column volumes of degassed 0.05% sodium azide.

IgY was affinity purified on this peptide-linked SULFOLINK gel according to a modified version of Rosol et al. *Veterinary Immunology and Immunopathology*, 35:321-337, 1993. Once at room temperature, the column was washed with 10 column volumes of PBS. IgY was recycled on the column for 2 hours. The column was then washed with 10 column volumes of PBS followed by 10 column volumes of phosphate buffered saline (PBS) with 0.5M

NaCl. Peptide-specific IgY was eluted with 500 mM glycine pH 2.5 and neutralized with 1M Tris pH 9.5. A UV spectrophotometer and graphing apparatus were used to follow the washing and elution of protein off the column. Samples with a signal at OD280 nm were concentrated in a centrprep
5 30 (Amicon) to a volume of 500-600 μ l.

Fab fragments ("Yab fragments") were made from affinity purified IgY incubated with immobilized pepsin (Pierce Chemical Company) according to product instructions and modified from the method of Akita and Nakai. *Journal of*
10 *Immunological Methods*. 162:155-164, 1993. Pepsin slurry was washed twice with 16 times the volume of 50 mM sodium acetate buffer pH 4.2, and resuspended in twice the volume of sodium acetate buffer. Affinity purified IgY was incubated with the immobilized pepsin at 37 =BOC and mixed for 5 hour. One molar Tris-HCl pH 8.0 was added to give a final pH of 7.5. The pepsin
15 mixture was centrifuged at 1000g for 5 min and the supernatant containing the fragments was added to a CENTRICON 10 filter (Amicon) to remove small Fc fragments. Complete cleavage was confirmed by SDS-PAGE.

Chicken serum from successive test bleeds and IgY extracted from batches of pooled egg yolks were tested by ELISA to confirm recognition of the
20 peptide. Affinity purified IgY and Fab' fragments ("Yab") were tested for their ability to recognize intact plgR by western blot. Cell lysates were made from Madin-Darby canine kidney (MDCK) cells and MDCK cells transfected with rabbit plgR ("pWe"), according to the method of Breitfeld *et al.* (*Methods in Cell Biology* 32:329-337 (1989)) using 10% NP40 lysis buffer containing 1
25 μ g/ml of protease inhibitors and phenylmethylsulfonyl fluoride (PMSF). Cell lysates were run on a 10% gel under reducing conditions and transferred onto a PVDF (polyvinylidene difluoride) membrane (Millipore, Bedford, MA). A mouse monoclonal antibody to the cytoplasmic portion of plgR, SC166 (Solari *et al.*, *Cell*, 36:61-71 (1984)), was used as a positive control antibody, and IgY
30 isolated from pre-immune yolks was used as a negative control.

HRP-conjugated rabbit anti-chicken IgY (Jackson Immunochemicals) and HRP-conjugated rabbit anti-mouse (Biorad) were used as secondary antibodies. IgY from a chicken injected with the primary peptide and IgY from a chicken

injected with the subsequence peptide recognized intact plgR, but IgY from one of the chickens injected with the subsequence antibody did not.

Immunofluorescence studies of IgY and Yab fragments (from chickens injected with the primary peptide) with MDCK and pWe cells grown on coverslips, fixed with 4% paraformaldehyde and permeabilized with saponin showed more specific staining of the plgR-transfected cells (FITC-conjugated rabbit anti-chicken and anti-mouse antibodies obtained from Jackson Immunochemicals). A cell ELISA (modified from M Hahne *et al.*, *Journal of Cell Biology*. 121:655-64, 1993) on fixed and permeabilized cells showed Yab fragment staining 5-fold greater with pWe cells than MDCK cells. These data demonstrate that we have successfully raised polyclonal antibodies against the rabbit plgR stalk peptide and that they recognize intact plgR.

Example 2

Example 2 describes selection of human recombinant single chain variable region fragment (scFv) antibodies by phage display.

Selection of scFv by phage display requires a soluble biotinylated antigen or antigen immobilized on a solid support. Because scFv selected by phage display tend to be low affinity binders and because the soluble antigen may allow selection of higher affinity scFv (R Schier *et al.*, *J. Mol. Biol.* 255:28-43, 1996), the selection approach with soluble antigen was chosen. The plgR stalk primary peptide, described in Example 1, corresponding to the 23 amino acids of the membrane-proximal extracellular part of the rabbit plgR was conjugated to biotin via the sulfhydryl group of the cysteine residue using biotin-BMCC ((1-Biotinamido-4-(4'-(maleimidomethyl)cyclohexane-carboxamido) butane) (Pierce Chemical Company, Rockford, IL) based on the method described in the product instructions. To ensure that the peptide had not dimerized via the sulfhydryl groups, the peptide was first reduced with 1% sodium borohydride in 0.1M Tris, 5mM EDTA pH 8.0. The pH of the solution was lowered to pH 5 by adding 1N HCl. Once the solution had finished fizzing, 1M Tris was added back to reach pH 7.0. A 8.5 mM biotin-BMCC solution was prepared by dissolving the biotinylation reagent in DMSO. A 5-fold molar excess of biotin-BMCC was added to the reduced peptide and incubated

overnight at 4°C. The biotinylated peptid was separated from free biotin by HPLC with a C18 column with a gradient ranging from 10 to 50% CH₃CN over 30 min, with UV detection at 215 nm. Mass spectrometry by electrospray and LSIMS (liquid secondary ion mass spectrometry) identified the correct peak
5 corresponding to the biotinylated peptide.

The biotinylated primary peptide was incubated with a phage library encoding a large number of different human scFv (approx. 10¹⁰). This phage library was prepared as previously described (JD Marks *et al.*, *J. Mol. Biol.* 222:581-97, 1991; JD Marks *et al.*, *Bio/Technology* 10:779-783, 1992;
10 JD Marks *et al.*, *Bio/Technology* 11:1145-1149, 1993; AD Griffiths *et al.*, *EMBO J* 12:725-734, 1993). A total of four rounds of selection, phagemid rescue and expansion in *Escherichia coli* suppressor strain TG-1 were performed as described in Marks *et al.* (*J. Mol. Biol.* 222:581-97, 1991) with the following modifications. The phage library used is known to contain several
15 streptavidin binders, so the first three rounds of selection included a preclearing step with two 30 min incubations of the phage with streptavidin agarose (Sigma). The phage were then incubated with 5 µg of biotinylated primary peptide for 1 hour. To bind the biotinylated peptide with the attached phage, the peptide-phage solution was incubated with avidin magnetic beads on the
20 first and third rounds for 15 and 5 minutes, respectively, and with streptavidin magnetic beads on the second and fourth rounds for 10 and 5 minutes, respectively. Rescued phage from the fourth round of selection were infected into *Escherichia coli* non-suppressor strain HB2151, and individual phagemid clones were induced to produce soluble scFv fragments with IPTG as described
25 in Marks *et al.* (*J. Mol. Biol.* 222:581-97, (1991)).

Bacterial supernatants from the individual clones were analysed for expression of soluble scFv fragments in a dot blot assay and for binding to biotinylated primary peptide in an ELISA assay (Finnern *et al.*, *Clin. Exp. Immunol.* 102:566-574, 1995). The ELISA assay, however, was modified in
30 the following manner: 96-well microwell plates (Immulon-4) were coated with avidin (10 µg/ml in phosphate buffered saline (PBS)) overnight at 4°C, washed 3 times with PBS, blocked with 2% milk in PBS and bound with biotinylated primary peptide (5 µg/ml in PBS). TMB (3,3',5,5' tetramethylbenzidine)

solution (Kirkegaard and Perry) was used as substrate (100 μ l/well), and the reaction was stopped with 0.18M H₂SO₄ before reading the color reaction in an ELISA reader at a wavelength of 450 nm. Dot blot analysis showed that 66% of the 96 selected colonies of HB2151 infected with phage rescued from the fourth round of selection produced scFv. ELISA assay showed that 43 of the 96 colonies produces scFv that bound to the peptide.

The diversity of all positive clones was determined by PCR screening. The scFv insert of the heavy and light chain was first amplified with the primers LMB3 and fd-Seq1 (Marks *et al.*, *J. Mol. Biol.* 222:581-97, 1991), and then digested with the restriction enzyme BstN1. Clones with different DNA fingerprint patterns were sequenced using a SequiTherm Long-Read cycle sequencing kit (Epicentre Technologies) and a Licor machine. Five unique sequences were identified.

To obtain large amounts of purified scFv for further characterization and use, the five unique scFv were subcloned into the expression vector pUC119 Sfi-NotmycHis, which adds a hexa-histidine tag at the C-terminal end of the scFv (Schier *et al.*, *J. Mol. Biol.*, 255:28-43, 1996).

Example 3

Example 3 describes targeting of the wildtype cystic fibrosis transconductance regulator (CFTR) gene into mammalian cells expressing plgR using a variation of the methods disclosed in Ferkol *et al.*, *J. Clin. Invest.*, 92:2394-2400 (1993); and Ferkol *et al.*, *J. Clin. Invest.*, 95:493-502 (1995), each of which is incorporated herein by reference.

An Fab fragment reactive to the stalk region of plgR is made and purified by techniques such as that disclosed in Example 1. The Fab is linked to poly (L-lysine) (MW 20,000 Daltons) using the heterobifunctional crosslinking reagent N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP) according to the method of Ferkol *et al.* (1993).

A plasmid comprising the CFTR gene is ligated to a cytomegalovirus early promoter and inserted into the vector pCB6. Thomas *et al.*, *J. Biol. Chem.*, 268:3313-3320 (1993). Complexes of Fab-polylysine-DNA are made by combining plasmid DNA with the Fab-polylysine in 3M NaCl.

The complex is introduced by dissolving it in 0.1 ml of phosphate buffered saline, and placing it into the nares of pathogen-free Sprague-Dawley rats (250-300 grams) lightly anesthetized with Metofane inhalant anesthesia. A micropipet will be used to apply 100 μ L of the plasmid in PBS directly into the nares of rats that are manually restrained in the supine position. Rats will be held in this position until the solution has been inhaled. This technique has been shown to result in effective application of the sample onto the nasal mucosa. Shahin *et al.*, *Infection and Immunity* 60:1482-1488 (1992); Gizurarson *et al.*, *Vaccine* 10:101-106 (1992). Transcription of the transfected gene is assayed by immunofluorescence assay of production of the CFTR protein.

Example 4

Example 4 describes a means of in vivo targeting of exogenous proteins into cells expressing plgR.

An efficient method to allow egress of proteins from endosomes will employ the protein-Fab complex coupled to adenovirus. This method has been used with a number of receptor systems resulting in as much as a 1000-fold increase in expression. Curiel *et al.*, *J. Respir. Cell Mol. Biol.* 6:247-252 (1992); Curiel *et al.*, *Proc. Natl. Acad. Sci. USA* 88:8850-8854 (1991), Gao *et al.*, *Hum. Gene Ther.* 4:17-24 (1993), each of which is incorporated herein by reference. Coupling is accomplished by biotinylation of the adenovirus and the Fab/poly-lysine followed by cross-linking with avidin. The resultant complex is administered as in Example 4.

Example 5

Example 5 describes transcytosis of antibodies, which specifically bind to the stalk, from the apical to basolateral membrane of a MDCK (Madin Darby canine kidney) cell comprising plgR.

Yab fragments reactive to plgR were made as described in Example 1. Anti-plgR stalk Yab fragments were radio-iodinated by the iodine monochloride method of Goldstein *et al.* (*Meth. Enzymol.* 96:241-249, 1983). Radio-iodinated IgA was used as a control ligand. Radio-iodinated Yab

fragments or IgA (10^7 cpm in 100 μ l/well) were added to the apical surface of MDCK and pWe cells grown in a polarized manner for 4 days on 12mm diameter, 0.4 μ m pore size cell culture inserts (Transwells, Costar). Breitfeld *et al.*, *Methods in Cell Biology* 32:329-337 (1989). Radio-labelled Yab fragments

5 were added to cells with and without a 2h preincubation with the protease inhibitor, leupeptin, 50 μ l/ml. After 20 min of apical uptake at 37°C, unbound radio-labelled ligand was washed with MEM (minimal essential medium)/BSA (bovine serum albumen) three times quickly, one 5 min wash and two more quick washes. The apical and basolateral media were collected and changed at

10 7, 15, 30, 60 and 120 min time points for quantitation in a gamma counter (Beckman Instruments, Palo Alto, CA). Cell culture inserts were cut out at 120 min for quantitation in a gamma counter and to calculate the total initial uptake of radioactivity. The background uptake by MDCK cells was subtracted from that by pWe cells to calculate specific recycling and transcytosis of the

15 radiolabeled ligands. The results showed that 13-18% of the Yab fragments were transcytosed from the apical to the basolateral surface of cells pretreated with leupeptin, in contrast to 5-6% of the IgA.

All publications and patents mentioned in this specification are herein incorporated by reference into the specification to the same extent as if

20 each individual publication or patent was specifically and individually indicated to be incorporated herein by reference.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT:
 - (A) NAME: The Regents of the University of California
 - (B) STREET: 300 Lakeside Drive, 22nd Floor
 - (C) CITY: Oakland
 - (D) STATE: California
 - (E) COUNTRY: USA
 - (F) POSTAL CODE (ZIP): 94612-3558
 - (G) TELEPHONE: (510) 748-6600
 - (H) TELEFAX:
 - (I) TELEX:
- (ii) TITLE OF INVENTION: Cellular Internalization of pIgR Stalk and Associated Ligands
- (iii) NUMBER OF SEQUENCES: 11
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Townsend and Townsend and Crew LLP
 - (B) STREET: Two Embarcadero Center, Eighth Floor
 - (C) CITY: San Francisco
 - (D) STATE: California
 - (E) COUNTRY: USA
 - (F) ZIP: 94111-3834
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: WO Not yet assigned
 - (B) FILING DATE: Not yet assigned
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 60/018,958
 - (B) FILING DATE: 04-JUN-1996
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Weber, Kenneth A.
 - (B) REGISTRATION NUMBER: 31,677
 - (C) REFERENCE/DOCKET NUMBER: 02307E-067910PC
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: (415) 576-0200
 - (B) TELEFAX: (415) 576-0300

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 4 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 3
- (D) OTHER INFORMATION: /product= "OTHER"
/note= "Xaa = polar or charged amino acid"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Phe Ala Xaa Glu
1

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 33 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Glu Arg Glu Ile Gln Asn Val Arg Asp Gln Ala Gln Glu Asn Arg Ala
1 5 10 15
Ser Gly Asp Ala Gly Ser Ala Asp Gly Gln Ser Arg Ser Ser Ser
20 25 30
Lys

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 31 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Glu Arg Glu Ile Gln Asn Ala Gly Asp Gln Ala Gln Glu Asn Arg Ala
1 5 10 15
Ser Gly Asn Ala Gly Ser Ala Gly Gly Gln Ser Gly Ser Ser Lys
20 25 30

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 31 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Glu Lys Ala Val Ala Asp Thr Arg Asp Gln Ala Asp Gly Ser Arg Ala
 1 5 10 15

Ser Val Asp Ser Gly Ser Ser Glu Glu Gln Gly Gly Ser Ser Arg
 20 25 30

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Glu Ser Val Lys Asp Ala Ala Gly Gly Pro Gly Ala Pro Ala Asp Pro
 1 5 10 15

Gly Arg Pro Thr Gly Tyr Ser Gly Ser Ser Lys
 20 25

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 40 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Leu Ala Glu Val Ala Val Gln Ser Ala Glu Asp Pro Ala Ser Gly Asp
 1 5 10 15

Pro Ala Ser Gly Ser Arg Ala Ser Val Asp Ser Gly Ser Ser Glu Glu
 20 25 30

Gln Gly Gly Ser Ser Arg Ser Lys
 35 40

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

31

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Asp Pro Ala Ser Gly Ser Arg Ala Ser Val Asp Ala Ser Ser Ala Ser
1 5 10 15
Gly Gln Ser Gly Ser Ala Lys
20

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Asp Pro Ala Ser Gly Ser Arg Ala Ser Val Asp Ala Ser Ser Ala Ser
1 5 10 15
Gly Gln Ser Gly Ser Ala Lys Cys
20

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Ala Ser Val Asp Ala Ser Ser Ala Ser Gly Gln Ser Gly Ser Ala Lys
1 5 10 15
Cys

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 61 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

32

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Asp | Ala | Ala | Pro | Asp | Glu | Lys | Val | Leu | Asp | Ser | Gly | Ph | Arg | Glu |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |
| Ile | Glu | Asn | Lys | Ala | Ile | Gln | Asp | Pro | Arg | Leu | Phe | Ala | Glu | Glu | Lys |
| | | | 20 | | | | | 25 | | | | | 30 | | |
| Ala | Val | Ala | Asp | Thr | Arg | Asp | Gln | Ala | Asp | Gly | Ser | Arg | Ala | Ser | Val |
| | | | 35 | | | | 40 | | | | | 45 | | | |
| Asp | Ser | Gly | Ser | Ser | Glu | Glu | Gln | Gly | Gly | Ser | Ser | Arg | | | |
| | 50 | | | | | 55 | | | | | 60 | | | | |

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 61 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Asp | Ala | Ala | Pro | Asp | Glu | Lys | Val | Leu | Asp | Ser | Gly | Phe | Arg | Glu |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |
| Ile | Glu | Asn | Lys | Ala | Ile | Gln | Asp | Pro | Arg | Leu | Phe | Ala | Glu | Glu | Lys |
| | | | 20 | | | | | 25 | | | | | 30 | | |
| Ala | Val | Ala | Asp | Thr | Arg | Asp | Gln | Ala | Asp | Gly | Ser | Arg | Ala | Ser | Val |
| | | | 35 | | | | 40 | | | | | 45 | | | |
| Asp | Ser | Gly | Ser | Ser | Glu | Glu | Gln | Gly | Gly | Ser | Ser | Arg | | | |
| | 50 | | | | | 55 | | | | | 60 | | | | |

WHAT IS CLAIMED IS:

1 1. A ligand that binds specifically to the stalk of a polymeric
2 immunoglobulin receptor (plgR) of a cell with the proviso that the ligand does
3 not substantially bind to secretory component of plgR under physiological
4 conditions.

1 2. A ligand of claim 1 wherein the ligand is an antibody.

1 3. A ligand of claim 1 wherein the ligand is a humanized
2 antibody.

1 4. A ligand of claim 1 wherein the ligand is a recombinant
2 single chain variable region fragment of an antibody.

1 5. A ligand of claim 1 which binds to an extracellular epitope
2 within the first 33 amino acids that are cell membrane proximal to a cleavage
3 site of the receptor.

1 6. A ligand of claim 1 which binds to a peptide selected from
2 the group of:

3 Mouse: Glu-Arg-Glu-Ile-Gln-Asn-Val-Arg-Asp-Gln-Ala-Gln-Glu-Asn-
4 Arg-Ala-Ser-Gly-Asp-Ala-Gly-Ser-Ala-Asp-Gly-Gln-Ser-Arg-Ser-Ser-Ser-Ser-Lys
5 (SEQ ID NO:2)

6 Rat: Glu-Arg-Glu-Ile-Gln-Asn-Ala-Gly-Asp-Gln-Ala-Gln-Glu-Asn-Arg-
7 Ala-Ser-Gly-Asn-Ala-Gly-Ser-Ala-Gly-Gly-Gln-Ser-Gly-Ser-Ser-Ser-Lys (SEQ ID NO:3)

8 Human: Glu-Lys-Ala-Val-Ala-Asp-Thr-Arg-Asp-Gln-Ala-Asp-Gly-Ser-
9 Arg-Ala-Ser-Val-Asp-Ser-Gly-Ser-Ser-Glu-Glu-Gln-Gly-Gly-Ser-Ser-Arg (SEQ ID
10 NO:4)

11 Bovine: Glu-Ser-Val-Lys-Asp-Ala-Ala-Gly-Gly-Pro-Gly-Ala-Pro-Ala-

12 Asp-Pro-Gly-Arg-Pro-Thr-Gly-Tyr-Ser-Gly-Ser-Ser-Lys (SEQ ID NO:5)

13 Rabbit: Leu-Ala-Glu-Val-Ala-Val-Gln-Ser-Ala-Glu-Asp-Pro-Ala-Ser-
14 Gly-Asp-Pro-Ala-Ser-Gly-Ser-Arg-Ala-Ser-Val-Asp-Ser-Gly-Ser-Ser-Glu-Glu-Gln-
15 Gly-Gly-Ser-Ser-Arg-Ser-Lys (SEQ ID NO:6).

1 7. A ligand of claim 1 which is further defined as having a
2 binding component for selectively binding to the receptor stalk and a
3 biologically active component wherein the biologically active component is
4 selected from the group consisting of a nucleic acid, protein, radioisotope,
5 lipids, and carbohydrates.

1 8. A ligand of claim 7 wherein the nucleic acid encodes the
2 wildtype cystic fibrosis transmembrane conductance regulator.

1 9. A method of introducing a ligand into a cell expressing a
2 polymeric immunoglobulin receptor by attaching the ligand to the stalk of the
3 polymeric immunoglobulin receptor of the cell with the proviso that the ligand
4 does not substantially bind to the secretory component of plgR under
5 physiological conditions.

1 10. A method of claim 9 wherein the ligand is an antibody.

1 11. A method of claim 9 wherein the ligand is a humanized
2 antibody.

1 12. A method of claim 10 wherein the ligand is a recombinant
2 single chain variable region fragment of an antibody.

1 13. A method of claim 9 wherein the ligand binds to an
2 extracellular epitop within the first 33 amino acids that are cell membrane
3 proximal to a cleavage site of the receptor.

1 14. A method of claim 9 wherein the ligand binds to a peptide
2 selected from the group of:

3 Mouse: Glu-Arg-Glu-Ile-Gln-Asn-Val-Arg-Asp-Gln-Ala-Gln-Glu-Asn-
4 Arg-Ala-Ser-Gly-Asp-Ala-Gly-Ser-Ala-Asp-Gly-Gln-Ser-Arg-Ser-Ser-Ser-Ser-Lys
5 (SEQ ID NO:2)

6 Rat: Glu-Arg-Glu-Ile-Gln-Asn-Ala-Gly-Asp-Gln-Ala-Gln-Glu-Asn-Arg-
7 Ala-Ser-Gly-Asn-Ala-Gly-Ser-Ala-Gly-Gly-Gln-Ser-Gly-Ser-Ser-Ser-Lys (SEQ ID NO:3)

8 Human: Glu-Lys-Ala-Val-Ala-Asp-Thr-Arg-Asp-Gln-Ala-Asp-Gly-Ser-
9 Arg-Ala-Ser-Val-Asp-Ser-Gly-Ser-Ser-Glu-Glu-Gln-Gly-Gly-Ser-Ser-Arg (SEQ ID
10 NO:4)

11 Bovine: Glu-Ser-Val-Lys-Asp-Ala-Ala-Gly-Gly-Pro-Gly-Ala-Pro-Ala-
12 Asp-Pro-Gly-Arg-Pro-Thr-Gly-Tyr-Ser-Gly-Ser-Ser-Ser-Lys (SEQ ID NO:5)

13 Rabbit: Leu-Ala-Glu-Val-Ala-Val-Gln-Ser-Ala-Glu-Asp-Pro-Ala-Ser-
14 Gly-Asp-Pro-Ala-Ser-Gly-Ser-Arg-Ala-Ser-Val-Asp-Ser-Gly-Ser-Ser-Glu-Glu-Gln-
15 Gly-Gly-Ser-Ser-Arg-Ser-Lys (SEQ ID NO:6).

1 15. A method of claim 9 wherein the ligand is further defined as
2 having a binding component for selectively binding to the receptor stalk and a
3 biologically active component wherein the biologically active component is
4 selected from the group consisting of a nucleic acid, protein, radioisotope, lipid,
5 and carbohydrate.

1 16. A method claim 15 wherein the nucleic acid encodes the
2 wildtype cystic fibrosis transmembrane conductance regulator.

1 17. A ligand of claim 1 which is further defined as having a
2 binding component for selectively binding to the receptor stalk and a
3 biologically active component wherein the biologically active component is

4 selected from the group consisting of anti-inflammatories, antisense oligos,
5 antibiotics, and anti-infectives.

1 18. A method of claim 9 wherein the cell is a mammalian cell.

1 19. A method of claim 18 wherein the cell is an epithelial cell.

1 20. The method of claim 9 wherein the ligand is attached to the
2 stalk at the apical surface of the cell.

1 21. The method of claim 20 wherein the ligand is transcytosed
2 to the basolateral side of the cell.

1 22. The method of claim 21, wherein the ligand is released from
2 the stalk at the basolateral surface of the cell.

1 23. The method of claim 9 wherein the ligand is attached to the
2 stalk at the basolateral surface of the cell.

1 24. The method of claim 9 wherein the ligand specifically binds
2 only to the stalk.

1 25. The ligand of claim 1 wherein the ligand specifically binds
2 only to the stalk.

1 26. A method of attaching a ligand to a cell expressing a
2 polymeric immunoglobulin receptor comprising the step of binding the ligand to
3 a stalk of the receptor with the proviso that the ligand does not substantially
4 bind to secretory component of plgR under physiological conditions.

1 27. The method of claim 26 wherein the ligand is endocytosed
2 into the cell after binding.

1 28. A ligand of claim 1 which binds to a peptide having the
2 sequence: Ala-Asp-Ala-Ala-Pro-Asp-Glu-Lys-Val-Leu-Asp-Ser-Gly-Phe-Arg-Glu-
3 Ile-Glu-Asn-Lys-Ala-Ile-Gln-Asp-Pro-Arg-Leu-Phe-Ala-Glu-Glu-Lys-Ala-Val-Ala-
4 Asp-Thr-Arg-Asp-Gln-Ala-Asp-Gly-Ser-Arg-Ala-Ser-Val-Asp-Ser-Gly-Ser-Ser-Glu-
5 Glu-Gln-Gly-Gly-Ser-Ser-Arg (SEQ ID NO:10).

1 29. A ligand of claim 9 wherein the ligand binds to the peptide
2 aving the sequence: Ala-Asp-Ala-Ala-Pro-Asp-Glu-Lys-Val-Leu-Asp-Ser-Gly-Phe-
3 Arg-Glu-Ile-Glu-Asn-Lys-Ala-Ile-Gln-Asp-Pro-Arg-Leu-Phe-Ala-Glu-Glu-Lys-Ala-
4 Val-Ala-Asp-Thr-Arg-Asp-Gln-Ala-Asp-Gly-Ser-Arg-Ala-Ser-Val-Asp-Ser-Gly-Ser-
5 Ser-Glu-Glu-Gln-Gly-Gly-Ser-Ser-Arg (SEQ ID NO:11).

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/07944

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07K 16/00

US CL : 530/387.1, 387.3

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/387.1, 387.3

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|---|-----------------------|
| Y | SOLARI et al. Distribution and processing of the polymeric immunoglobulin receptor in the rat hepatocyte: Morphological and biochemical characterization of subcellular fractions. J. Histochemistry Cytochemistry. 1986, Vol. 34, No. 1, pages 17-23. See entire document. | 1-29 |
| Y | FERKOL et al. Gene transfer into respiratory epithelial cells by targeting the polymeric immunoglobulin receptor. J. Clin. Invest. November 1993, Vol. 92, pages 2394-2400. See entire document. | 1-29 |
| Y | MOSTOV et al. Transepithelial transport of immunoglobulins. Ann. Rev. Immunol. 1994, Vol. 12, pages 63-84. See entire document. | 1-29 |

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

| | |
|--|--|
| * Special categories of cited documents: | "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention |
| "A" document defining the general state of the art which is not considered to be of particular relevance | "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone |
| "E" earlier document published on or after the international filing date | "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| "L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | "&" document member of the same patent family |
| "O" document referring to an oral disclosure, use, exhibition or other means | |
| "P" document published prior to the international filing date but later than the priority date claimed | |

Date of the actual completion of the international search

15 AUGUST 1997

Date of mailing of the international search report

09 SEP 1997

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Authorized officer

MINH-TAM DAVIS

Facsimile No. (703) 305-3230

Telephone No. (703) 308-0916

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/07944

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|--|-----------------------|
| Y | PISKURICH et al. Molecular cloning of the mouse polymeric Ig receptor. J. Immunol. 1995, Vol. 154: 1735-1747. See entire document. | 1-29 |
| Y | MAZANEC et al. Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies. J. Virol. February 1995, Vol. 69, No.2, pages 1339-1343. See entire document. | 1-29 |
| Y | WILLIAMS, G. Novel antibody reagents: production and potential. TIBTECH. February 1988, Vol. 6, pages 36-42. See entire document. | 1-29 |

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/07944

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, DIALOG, MPSRCH

search terms: polymeric immunoglobulin receptor, pIgR, antibody, humanized, single chain, ligand, secretory component, extracellular